Details

Autor(en) / Beteiligte

• Beyar-Katz, Ofrat
• Lavi, Noa
• Ringelstein-Harlev, Shimrit
• Henig, Israel
• Yehudai-Ofir, Dana
• Haddad, Nuhad
• Fineman, Riva
• Ofran, Yishai
• Nov, Yuval
• Sahar, Dvora
• Moustafa-Hawash, Nivin
• Rowe, Jacob M.
• Zuckerman, Tsila

Titel

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation

Ist Teil von

• Leukemia & lymphoma, 2019-08, Vol.60 (10), p.2449-2456

Ort / Verlag

United States: Taylor & Francis

Erscheinungsjahr

2019

Beschreibungen/Notizen

• Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18 - inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) (p = .001) and overall survivals (OS) (p = .0007). The 1-year RFS and OS were 44.2% vs 88% and 71% vs 96% for chemotherapy and ASCT, respectively. The corresponding TRM was 4/40 (10.0%) and 0/26 (0%), with relapse rates of 70.0% and 19.2% (p = .0002). In multivariate analysis, ASCT was associated with superior OS and RFS. In conclusion, ASCT offers significantly superior RFS and OS in favorable-risk AML in first complete remission. These data support the recent resurgence of interest in ASCT for AML.